Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label setmelanotide study in young children with rare genetic obesity
2021-004167-27Phase 3Terminated
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Oct 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of setmelanotide in obesity, leptin receptor deficiency and Bardet–Biedl syndrome (BBS), sponsored by Rhythm Pharmaceuticals. Primary endpoint: Responder rate based on BMI z-score. Started Oct 2021; status: terminated.
02
Drugs
setmelanotide
03
Conditions
obesityleptin receptor deficiencyBardet–Biedl syndrome (BBS)
Beyond the preview
Go deeper on 2021-004167-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004167-27.